AC Immune SA (ACIU) Earnings Date & Reports

Key Takeaways

• AC Immune is expected to report third-quarter 2026 results before the market opens in early November, followed by a conference call.
• Wall Street consensus projects a net loss of about $0.22 per share, compared with a loss of $0.20 in the same quarter a year ago.
• Analysts model roughly $0.33 million in revenue, a sharp decline from $1.18 million a year earlier, reflecting milestone-driven lumpiness.
• In its prior quarter, the company swung to earnings per share (EPS) of $0.03 on $18.67 million in revenue, boosted by a milestone payment.
• Cash runway and research and development (R&D) spending remain central as the company advances its Alzheimer's and Parkinson's programs.
• The stock has lagged over the past year, sharpening investor focus on guidance and pipeline catalysts.
• Get more details on the ticker's Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
• Explore Trending AI Robots to discover AI-driven trading strategies and market ideas.

Earnings Context and Why It Matters

AC Immune is a Swiss clinical-stage biopharmaceutical company developing precision medicines for neurodegenerative diseases such as Alzheimer's and Parkinson's. Because it generates limited product revenue, its quarterly results hinge on collaboration income and milestone payments, which can swing dramatically from one period to the next. For investors, the report is less about headline profitability and more about three signals: how efficiently the company is spending its cash, whether key clinical programs are progressing on schedule, and whether the balance sheet provides enough runway to reach the next data readouts. Given the stock's elevated short interest and a 52-week decline, this update carries added weight for sentiment.

Earnings Expectations

Consensus estimates call for AC Immune to post a loss of approximately $0.22 per share on revenue of about $0.33 million for the third quarter of 2026. That compares with a loss of $0.20 per share and revenue of $1.18 million in the prior-year period, implying a revenue decline of roughly 72%. The expected drop largely reflects the timing of collaboration and milestone revenue rather than underlying weakness. Notably, the company beat EPS estimates in five of its last eight quarters, and its most recent report, for Q2 2026, swung to a profit of $0.03 per share on $18.67 million in revenue after a milestone payment. Beyond the headline figures, investors will watch R&D expenses, net cash, and any updates on clinical enrollment and partnership milestones.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following AC Immune, it offers a practical way to track shifts in the biotechnology sector and identify related setups as earnings season unfolds.

Market Reaction and Investor Sentiment

Sentiment heading into the print is cautious. AC Immune shares have declined over the past 52 weeks, and the stock carries a beta of about 1.55, meaning it tends to be more volatile than the broader market. Short interest stands near 7.6% of shares outstanding, a level that can amplify both upside and downside moves around a catalyst. Still, analyst sentiment remains constructive, with a consensus rating generally characterized as a "Buy" and a mean price target well above the current price. The key risk is that, without a fresh milestone or positive clinical update, a routine quarterly loss may do little to shift the narrative, leaving the stock exposed to profit-taking or continued drift.

Forward Outlook and Key Factors to Monitor

Looking ahead, the most important factor is the company's cash position and how far it extends the operating runway. AC Immune ended recent periods with a net cash position well above its market value on a per-share basis, but ongoing R&D spending means that runway depends on disciplined cost control and the arrival of future milestone payments.

Investors should also watch for progress across the Alzheimer's and Parkinson's portfolio. Enrollment updates, regulatory feedback, and any new or expanded partnerships are likely to matter more to the stock than a single quarter's revenue figure. Because collaboration income is lumpy, quarter-to-quarter comparisons can be misleading; the longer-term trajectory of partnered programs is the better signal.

Finally, pay attention to guidance and management commentary on the earnings call. Any adjustment to spending plans, updated timelines for data readouts, or changes to the pipeline's prioritization could shape expectations for 2027, when consensus currently models a return toward profitability. As always, these observations are informational and should be weighed alongside a full review of the company's disclosures.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations